Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer - implications for dosing schedule and neoadjuvant study consideration

By Hall M.C.   Fritzsch R.J.   Sagalowsky A.I.   Ahrens A.   Petty B.   Roehrborn C.G.  

Urology, Vol. 53, Iss. 5, 1999-05 ,pp. : 898-902

Elsevier

Access to resources Recommend Favorite

Protection of the germinal epithelium in the rat from the cytotoxic effects of chemotherapy by a luteinizing hormone-releasing hormone agonist and antiandrogen therapy

By Cespedes R.D.   Peretsman S.J.   Thompson I.M.   Jackson C.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 688-691

Elsevier

Access to resources Recommend Favorite

Menstruation recovery after chemotherapy and luteinizing hormone-releasing hormone agonist plus tamoxifen therapy for premenopausal patients with breast cancer

By Sakurai Kenichi   Matsuo Sadanori   Enomoto Katsuhisa   Amano Sadao   Shiono Motomi  

Surgery Today, Vol. 41, Iss. 1, 2011-01 ,pp. : 48-53

Springer Publishing Company

Access to resources Recommend Favorite

Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide

By Braslis K.G.   David R.C.   Nelson E.   Civantos F.   Soloway M.S.  

Urology, Vol. 45, Iss. 2, 1995-02 ,pp. : 329-331

Elsevier

Access to resources Recommend Favorite

Luteinizing hormone-releasing hormone agonists and meningioma: a treatment dilemma

By Lee K.L.   Terris M.K.  

Urology, Vol. 62, Iss. 2, 2003-08 ,pp. : 351-351

Elsevier

Access to resources Recommend Favorite